Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1096
Shown on this page
12
Current sort
Recently updated
Campus scope
Mount Sinai, New York, NY
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within Mount Sinai, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 661–672 of 1,096 matching trials with a site at Mount Sinai, New York, NY.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Active, not recruiting Phase 3 Interventional Results available

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495
Site status not listed — check the official record
View directory record Official record
Conditions
Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Primary Myelofibrosis
Interventions
Pelabresib, Placebo, Ruxolitinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 27, 2026, 10:19 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT02598661
Site status not listed — check the official record
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Imetelstat Sodium, Placebo
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 30, 2026, 3:47 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Community-based Implementation of Online EmReg

NCT05933629
Status at this site: Recruiting
View directory record Official record
Conditions
Emotion Regulation, Traumatic Brain Injury
Interventions
Consultation Sessions, Online EmReg
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 28, 2026, 5:55 PM EDT
Recruiting Not applicable Interventional

Imaging Coronary Microvascular Dysfunction (CMD) Study

NCT05634031
Status at this site: Recruiting
View directory record Official record
Conditions
Angina, Non-obstructive Coronary Artery Disease
Interventions
Coronary CT angiogram, Functional Angiography, PET imaging, Treadmill exercise stress study
Radiation · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 30, 2026, 8:19 AM EDT
Active, not recruiting Phase 3 Interventional Results available

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414
Site status not listed — check the official record
View directory record Official record
Conditions
Anemia, Myelofibrosis, Myeloproliferative Disorders, Post-Polycythemia Vera Myelofibrosis, Primary Myelofibrosis
Interventions
ACE-536, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
14
States / cities
Los Angeles, California • Orlando, Florida • Plantation, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 27, 2026, 11:13 PM EDT
Active, not recruiting Phase 3 Interventional

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124
Site status not listed — check the official record
View directory record Official record
Conditions
Bladder Cancer
Interventions
Cisplatin, Enfortumab vedotin (EV), Gemcitabine, Pembrolizumab, RC + PLND
Drug · Biological · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 27, 2026, 11:46 PM EDT
Active, not recruiting Phase 2 Interventional

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

NCT02724579
Site status not listed — check the official record
View directory record Official record
Conditions
Medulloblastoma
Interventions
Cisplatin, Cyclophosphamide, Laboratory Biomarker Analysis, Lomustine, Magnetic Resonance Imaging, Radiation Therapy, Vincristine, Vincristine Sulfate
Drug · Other · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
173
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 134 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 15, 2026, 10:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Neonatal Neurological Observation With Video AI

NCT07628829
Status at this site: Recruiting
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy, Neonatal Encephalopathy, Sedation, Sleep
Interventions
Continuous bedside video monitoring with AI anatomic landmark tracking for neurologic monitoring
Device
Lead sponsor
Artemis AI Labs
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Aug 2, 2026, 1:58 AM EDT
Recruiting Phase 1 Interventional

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

NCT06657144
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
5 Fluorouracil, CHS-114, Cisplatin, Toripalimab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 20, 2026, 9:37 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Health-E You Efficacy Trial for Male Adolescents

NCT06525064
Status at this site: Recruiting
View directory record Official record
Conditions
Reproductive Health, Sexual Health, Sexually Transmitted Diseases
Interventions
Health-E You app
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 21 Years · Male only
Enrollment
2,752 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
8
States / cities
Oakland, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 14, 2026, 7:33 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

NCT05800015
Site status not listed — check the official record
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Placebo, cemiplimab, fianlimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
29
States / cities
Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 29, 2026, 10:15 AM EDT
Recruiting Phase 3 Interventional

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

NCT06686771
Status at this site: Recruiting
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
First or second-line standard of care therapy, SBRT
Other · Radiation
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
71
States / cities
Phoenix, Arizona • Duarte, California • Irvine, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 14, 2026, 12:29 PM EDT

About this Mount Sinai institution page

What this page lists
ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.